Abstract
It has been shown that peripheral injections of Olan induce Fos activation in neurons of the lateral hypothalamus/ perifornical area and that a large part of these activated neurons are Orexin A-positive (Stephanidis et al., 2009). In ongoing experiments we aim to confirm the involvement of the central Orexin system in the metabolic side-effects of Olan by comparing the hyperglycemic effects of IG Olan infusions between animals treated ICV with an Orexin A antagonist or Vehicle.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Corresponding author
Additional information
1Netherlands Institute for Neuroscience, Amsterdam, The Netherlands, 2Department of Endocrinology and Metabolism, and 3Laboratory of Endocrinology, Department of Clinical Chemistry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. E-mail: e.girault@nin.knaw.nl
About this article
Cite this article
Girault, E., Foppen, E., Ackermans, M. et al. PS1 - 2. Involvement of the hypothalamic Orexin system in Olanzapine induced metabolic side-effects. NED. TIJDSCHR. DIABET. 9, 91–92 (2011). https://doi.org/10.1007/s12467-011-0027-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12467-011-0027-2